Searchable abstracts of presentations at key conferences in endocrinology

ea0090p424 | Pituitary and Neuroendocrinology | ECE2023

The acro-TIME score: a new clinical, pathological and immune integrative approach to early identify acromegaly patients resistant to treatment with first generation somatostatin ligands

Chiloiro Sabrina , Giampietro Antonella , Gessi Marco , Lauretti Liverana , Mattogno Pierpaolo , Costanza Flavia , Carlino Angela , Olivi Alessandro , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Doglietto Francesco , Bianchi Antonio

Somatotropinomas are benign pituitary tumors, with a heterogenous biological and clinical behavior. Tumor microenvironment reflects the interaction between tumor cells and the host immune system and may regulate tumor behavior and therapy outcome. We develop a scoring system that includes clinical, pathological and immune markers to early identify fg-SRLs resistant acromegaly pts. 43 acromegaly pts were included according the following criteria (1) first line treatment with su...

ea0090p438 | Pituitary and Neuroendocrinology | ECE2023

The Role of the GH Receptor Polymorphism as Prognostic Factor of Vertebral Fractures in Acromegaly Patients Resistant to First Generation SSAs and Treated with GH Receptor Antagonist or Second-Generation Somatostatin Ligand

Costanza Flavia , Chiloiro Sabrina , Giampietro Antonella , Mattogno Pierpaolo , Amato Infante , Angelini Flavia , Lauretti Liverana , Olivi Alessandro , Pontecorvi Alfredo , Doglietto Francesco , De Marinis Laura , Bianchi Antonio

Acromegaly is associated with skeletal fragility and an increased prevalence of vertebral fractures (VF). In recent years several authors have tried to investigate the markers that can predict the risk of bone fragility in this endocrine disorder. Two different isoforms of the GH receptor (GHR) have been described so far, which differ in the presence or absence of a transcript of exon 3 of the GHR gene. Both isoforms produce a functional receptor, but the exon 3-deleted isofor...